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Abstract 18 
Background: Colostrum provides an immune sharing between a mother and her infant. The 19 
transfer in colostrum of antibodies against SARS-CoV-2 and the elicited cytokines may provide 20 
crucial protection to the infant. There is limited literature on the immune response to SARS-21 
CoV-2 present in colostrum.  22 
Objective: To evaluate the presence of antibodies specific to SARS-CoV-2 and the associated 23 
cytokines in colostrum from women who tested positive for the virus. 24 
Study Design: Between March and September 2020 we obtained bilateral colostrum samples 25 
collected on spot cards within 48 hours of delivery from 15 new mothers who had previously 26 
tested positive for SARS-CoV-2. Five of these 15 COVID-19 positive women also provided 27 
bilateral liquid colostrum within 1-2 days of providing the spot card samples. Archived bilateral 28 
colostrum samples collected from 8 women during 2011-2013 were used as pre-COVID-19 29 
controls. All samples were tested for reactivity to the Receptor Binding Domain (RBD) of the 30 
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 2 
SARS-CoV-2 spike protein using an ELISA that measures SARS-CoV-2 RBD-specific IgA, 31 
IgG, and IgM, and for concentrations of 10 inflammatory cytokines (IFNg, TNFa, IL-1b, IL-2, 32 
IL-4, IL-6, IL-8, IL-10, IL-12, IL-13) using a multiplex electrochemiluminescent sandwich 33 
assay.  34 
Results: Bilateral colostrum samples from 73%, 73% and 33% of the 15 COVID-19 mothers 35 
exhibited IgA, IgG, and IgM reactivity to RBD respectively. Colostrum samples from two of the 36 
8 pre-pandemic controls showed IgA and IgG reactivity to RBD. Additionally, COVID-19 37 
mothers had significantly higher levels of 9 of the 10 inflammatory markers (all except IFNg) as 38 
compared to the pre-COVID-19 controls. Comparable results were obtained with both the spot 39 
card-eluates and liquid samples.  40 
Conclusions: A strong humoral immune response is present in the colostrum of women who 41 
were infected with SARS-CoV-2 before delivering. High levels of 9 inflammatory markers were 42 
also present in the colostrum. The evolution and duration of the antibody response, as well as 43 
dynamics of the cytokine response, remain to be determined. Our results also indicate that future 44 
large-scale studies can be conducted with milk easily collected on paper spot cards. 45 
 46 
INTRODUCTION 47 
The Center for Disease Control and Prevention and the World Health Organization (WHO) 48 
recommend breast-feeding for mothers infected with SARS-CoV-2, as the benefits of mother’s 49 
milk are thought to outweigh potential risks of transmitting the virus to the infant1,2. A recent 50 
systematic review, reporting on 77 nursing mothers from 37 studies concluded that there was no 51 
convincing evidence of transmission of SARS-CoV-2 via breastmilk3. As of December 14th, 52 
2020, the WHO reported over 71 million people infected by SARS-CoV-2 globally, and over 1.5 53 
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million deaths. As the number of pregnant and lactating SARS-CoV-2-infected women 54 
increases, there is a need to build on existing, yet limited, research on SARS-CoV-2-specific-55 
antibodies and immune response in breast milk from infected women. Antibodies to SARS-CoV-56 
2 and cytokines in breast milk are relevant to the health of nursed babies and mothers1,2,4,5. 57 
Multiple studies have reported an increase in inflammatory cytokines in the serum and 58 
bronchoalveolar lavage fluid of COVID-19-infected individuals6–12. However, there are no 59 
reports on the cytokine profiles in breast milk of women with COVID-19. Published literature 60 
suggests that the transfer of cytokines via breast milk can impact an infant’s immune system, 61 
conferring protection against various infectious diseases and allergies13,14. We15,16 and 62 
others13,14,17 have measured cytokines in breast milk and colostrum. Understanding cytokine 63 
profiles in breast milk of COVID-19-infected women is particularly relevant, as a preliminary 64 
study indicates that expression of ACE2 is elevated in the mammary epithelium during 65 
pregnancy, and through JAK-STAT pathways cytokines can influence ACE2 promoter 66 
activation18. Antibody-mediated protection from SARS-CoV-2 in breast milk has clinical 67 
implications regarding the discussion about breast-feeding after infection. Prolonged antibody 68 
presence may ultimately influence the maternal decision to breast-feed and aid in the support a 69 
mother receives post-partum. The present study details findings regarding SARS-CoV-2-specific 70 
IgA, IgG, and IgM, and cytokine profiles in bilateral samples of colostrum collected within the 71 
first few days after parturition from 15 infected women and compares these results to colostrum 72 
obtained from pre-COVID-19 samples collected during 2011-2013. 73 
 74 
MATERIALS AND METHODS 75 
Recruitment of COVID-19-positive participants 76 
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Study participants were patients at UMass Memorial Medical Center (UMMC, Worcester, MA) 77 
and provided consent in accordance with an IRB-approved protocol (H00020140). Fifteen 78 
participants who tested positive, and one participant (P01) who tested negative for the SARS-79 
CoV-2 RNA, provided bilateral colostrum on the day of, or the day after delivery. Participants 80 
hand-expressed colostrum from each breast onto spot cards (Whatman® FTA® card, Millipore 81 
Sigma, #WHAWB120205); which were left to dry at room temperature (RT). 82 
Of the 16 participants who provided bilateral colostrum on spot cards, six participants 83 
also provided liquid bilateral colostrum within two days after providing the spot card samples. 84 
Participants hand-expressed or pumped colostrum equivalent to 5-10 mL from each breast into 85 
containers. The spot cards and liquid samples were stored at -80°C at UMMC until transferred to 86 
the laboratory at UMass Amherst at which point the spot cards were stored at RT and the liquid 87 
samples were stored at -20°C.   88 
 89 
Selection of pre-COVID-19 controls  90 
We identified archived samples from eight women who donated liquid bilateral colostrum (1-3 91 
days post-partum) during June 2011-May 2013. These colostrum samples were obtained 92 
following IRB-approved protocols. 93 
 94 
Processing bilateral colostrum samples on spot cards 95 
Discs (6 mm diameter) prepared from spot cards were heat-treated for 30 minutes at 56°C to 96 
inactivate any virus and were then resuspended in 500 µL of Tris-buffered saline with 0.1% 97 
Tween 20® (TBST) in a 24-well plate. The plate was incubated with gentle shaking overnight at 98 
4°C after which the TBST-eluates were used for detection of anti-SARS-CoV-2-specific 99 
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immunoglobulins. Extra eluates were stored at 4°C and used for the analysis of cytokines within 100 
72 hours.   101 
 102 
Processing liquid bilateral colostrum from COVID-19 and pre-COVID-19 samples to 103 
obtain a whey fraction.   104 
Briefly, 500 µL of colostrum was centrifuged at 820g for 8 minutes. The whey fraction was 105 
transferred to a 2 mL centrifuge tube and heat-treated for 30 minutes at 56°C. Samples from the 106 
whey fraction were used for the detection of anti-SARS-CoV-2-specific immunoglobulins. Extra 107 
whey fractions were stored at 4°C and used for the analysis of cytokines within 72 hours. 108 
 109 
Enzyme-Linked Immunosorbent Assay (ELISA) for the detection of anti-SARS-CoV-2 110 
IgA, IgG and IgM 111 
A SARS-CoV-2 ELISA was developed and validated at UMass Amherst. The receptor binding 112 
domain (RBD) spike protein cloned into the pCAGGS expression vector was expressed in 113 
HEK293T cells (ATCC) using PEI (10:1 PEI:DNA ratio) and purified by gravity flow, as 114 
described in Stadlbauer et al19. Briefly, 96-well plates (Fisher Sci., #351172) were coated with 115 
the RBD spike protein at 1 µg/mL in 1X phosphate-buffered saline and incubated with gentle 116 
shaking overnight at 4°C, followed by blocking in 5% (w/v) dry skimmed milk in TBST with 117 
gentle shaking for 30 minutes at RT. Fifty microliters of sample were added and incubated with 118 
gentle shaking for 1 hour at RT. Wells were then washed with TBST and incubated with 119 
horseradish peroxidase (HRP)-conjugated goat anti-human-IgA, goat anti-human-IgG, or goat 120 
anti-human-IgM at 1 µg/mL (Jackson Laboratory). Plates were washed 3 times, incubated with 121 
2,2'-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt (ATBS; Sigma Aldrich, 122 
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#A9941) diluted at 0.2 mg/mL in 0.1 M Sodium Acetate pH 4.5 at 370C for 30 minutes. Known 123 
concentrations of anti-Spike-RBD-human (h) IgG1, -hIgM and -hIgA1 (InvivoGen, San Diego, 124 
CA, #C3022) were assayed in the ELISAs. The concentration of the highest standard was 1250 125 
ng/mL; subsequent standards were prepared by 10-fold serial dilutions starting from 500 ng/mL 126 
to 0.05 ng/mL. After background subtraction, concentration curves for IgA, IgG and IgM were 127 
generated using a four-parametric logistic (4PL) curve with Excel’s Solver Add-In. 128 
Concentrations of unknown samples were calculated using the 4PL equation. 129 
 130 
Analysis of cytokines 131 
Cytokines were measured in a multiplex assay (Mesoscale Discovery, Gaithersburg, MD) 132 
according to the manufacturer’s instructions using 10-plex human V-PLEX Proinflammatory 133 
Panel 1 plates. Each 96-well plate included an 8-point standard curve and assays for ten 134 
cytokines: IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-1, IFN-g, TNF-a (upper and lower 135 
limits of detection are in Table S1). Samples and standards were run in technical duplicates.  136 
 137 
Data Analysis 138 
Welch’s t-test was used to assess differences in age and BMI between donations made during 139 
2020 and during 2011-2013. Student’s t-test was used to compute differences between cytokines. 140 
P-values < 0.05 were considered statistically significant after Bonferroni correction. Multiple 141 
linear regression using the lm() function was performed in R (version 4.0.2) to assess correlations 142 
between levels of anti-RBD IgA, IgG and IgM and cytokines.  143 
 144 
RESULTS 145 
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Participant Demographics 146 
Demographic characteristics of the 24 women are summarized in Table 1, stratified by the 147 
period of colostrum donation: ‘2020’ (COVID-19) versus ‘2011-2013’ (Pre-COVID-19 148 
controls). Groups did not differ significantly by age or BMI. Colostrum collected during 2011-149 
2013 was exclusively from women who identified as White (one woman did not provide 150 
information on race). Women who provided colostrum in 2020 were more diverse: they self-151 
identified as 31% Hispanic, 13% White Hispanic, 50% non-Hispanic White, and one woman 152 
identified as Asian American.        153 
Eleven of the 15 participants tested positive for COVID-19 near the time of delivery (0-4 154 
days (Figure 1). The 4 participants who did not test positive near the time of delivery (P13, P14, 155 
P15, and P16), had their most recent positive test 16 to 116 days before delivery (Figure 1). Six 156 
of the 15 COVID-19pos participants reported no symptoms. All of the participants reporting no 157 
symptoms (P02, P04, P05, P08, P10 and P11) had their first positive test within 1-3 days of 158 
delivery. Onset of symptoms for the remaining 9 participants occurred between 27-144 days 159 
before delivery (Figure 1). Eight of the 9 participants reported that onset of symptoms occurred 160 
at the time of the first positive test; the ninth participant (P09) reported onset of symptoms 18 161 
days before her first positive test.  162 
[Table 1 and Figure 1 here]  163 
 164 
Colostrum obtained from COVID-19pos participants exhibited strong reactivity to anti-165 
RBD IgA, IgG, and IgM.  166 
IgA, IgG, and IgM reactivities were measured in bilateral colostrum samples on spot 167 
cards. Samples were collected within 48 hours of delivery from 15 women who had positive 168 
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 8 
SARS-CoV-2 (COVID-19pos) tests, and one woman (P01) who tested negative for SARS-CoV-2. 169 
Five of the 15 COVID-19pos participants and P01 also provided liquid bilateral colostrum 170 
samples within 2 days after providing the spot card sample. Eight liquid bilateral colostrum 171 
samples donated as part of other studies during 2011-2013 served as pre-pandemic controls. All 172 
samples were tested in technical replicates. The low mean CVs of 3.21%, 3.9% and 4.4% for 173 
IgA, IgG and IgM assays respectively (Figure S1) demonstrate the high precision of the assay. 174 
Positive cut-off values for each assay were set at twice the mean OD levels for 175 
secondary-only antibody reactivities (background). The binding reactivities of IgA, IgG and IgM 176 
were similar between colostrum obtained from left and right breasts (Figure 2A, B, and C). For 177 
spot cards, Figures 2A & 2B show that colostrum was reactive to the RBD spike protein in 178 
samples from 14 of 15 participants for IgA and IgG, and 6 of 15 for IgM. The colostrum from 179 
only one COVID-19pos participant (P15), had no reactivity to the RBD spike protein. Of the 6 180 
participants who provided both spot card and liquid colostrum samples (P01-P06), the overall 181 
reactivities appear similar, but with a few differences. Reactivities for IgA, IgG and IgM were 182 
higher in the first donation (spot card) than in the second donation (liquid) for P03 and P06, 183 
while this pattern was reversed for P04 (Figure 2A).  184 
There is a strong relationship between having experienced symptoms and time since first 185 
positive test. Six participants (P02, P04, P05, P08, P10, and P11) had their first positive 186 
diagnostic test within 1-3 days of delivery, and none reported any symptoms, whereas all of the 187 
participants whose first diagnostic test was >25 days before delivery reported symptoms (Figure 188 
S2). In contrast, neither the time since first positive test nor whether the participant experienced 189 
symptoms were related to the antibody reactivity to RBD spike protein. Among women who 190 
tested positive at the time of delivery, the highest reactivities occurred in P06 and P10, who had 191 
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their first positive test 30 days (symptomatic) and 1 day (asymptomatic), respectively, before 192 
delivery (Figure S2). Among the 6 women who did not have a positive test at delivery (P03, 193 
P09, P13 and P15 tested negative at delivery; P14 and P16 were not re-tested at delivery), all of 194 
whom had symptoms, the highest reactivity to RBD occurred in P03 and P16, who had their first 195 
positive test 42 and 144 days, respectively before delivery, while P15 had no reactivity and her 196 
first positive test 98 days before delivery (Figure S2).   197 
Bilateral colostrum from 2 of 8 pre-COVID-19 control participants (P23 and P24), 198 
exhibited reactivities for IgA and IgG (Figure 2C). Colostrum from the left breast of pre-199 
COVID-19 control, P20, also exhibited reactivities for IgA and IgG, albeit low (Figure 2C). 200 
Because we did not have a dilution factor associated with antibody extraction from the spot card, 201 
the statistical comparison of antibody levels between the COVID-19pos and pre-COVID-19 202 
controls was restricted to liquid samples.  203 
The median IgA, IgG and IgM concentrations were 22.25 ng/mL versus 12.02 ng/mL; 204 
8.47 ng/mL versus 4.50 ng/mL; and 93.89 ng/mL versus 30.27 ng/mL in colostrum obtained in 205 
2020 and during 2011-2013 respectively (Figure S3). The greatest difference in antibody levels 206 
between COVID-19 participants and pre-COVID-19 controls was for IgM (p<0.0001), which 207 
showed a 3-fold higher concentration in the COVID-19pos samples.  208 
 209 
Elevated inflammatory markers in colostrum from COVID-19pos participants.  210 
Cytokines were measured in bilateral colostrum from COVID-19pos and pre-COVID-19 211 
participants. Among the COVID-19pos participants, most analytes were detected in the majority 212 
of samples, and this was true for cytokines measured in liquid milk as well as in spot card-eluates 213 
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(Table 2). In contrast, among the pre-COVID-19 controls, only one analyte, IL-8, was detected 214 
in all samples (Table 2).  215 
Cytokine concentrations were higher among COVID-19pos participants as compared to 216 
pre-COVID-19 controls, and again this was the case for both liquid colostrum and spot card-217 
eluates (except for IFNg and IL-6, which were not higher in the spot card). However, the 218 
concentration of cytokines was higher in the liquid colostrum than in the spot card-eluates for all 219 
analytes (Table 2). Because we did not have a dilution factor associated with the spot card 220 
extraction, statistical comparison between COVID-19pos and pre-COVID-19 samples was limited 221 
to the liquid colostrum.  222 
Among liquid samples, significantly elevated concentrations for 9 of 10 cytokines were 223 
observed in the COVID-19pos group (2020) (Figure 3). Only IFNg was not significantly higher. 224 
Moreover, there is an indication that cytokine levels in bilateral colostrum obtained from 225 
symptomatic participants were higher (red-filled circles; Figure 3) compared to levels in 226 
asymptomatic participants. This distinction was particularly clear for IL-2, IL-4, IL-6, IL-10 and 227 
IL-12. Additionally, we explored the association between antibody response and cytokine levels 228 
and found that SARS-CoV-2-specific IgA, IgG and IgM were negatively correlated to IL-13 in 229 
spot card-eluates (Table 3). This pattern was not detected in liquid colostrum from pre-COVID-230 
19 controls (Table S2). 231 
 232 
[Table 2 here] 233 
[Table 3 here] 234 
 235 
DISCUSSION 236 
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Principal findings  237 
Our results provide a snapshot of the dynamic immune response in colostrum following 238 
SARS-CoV-2 infection, confirming recent findings on the presence of SARS-CoV-2-specific 239 
antibodies in milk from infected women4,5, and describing for the first time, the associated 240 
cytokine profile. Colostrum samples archived before the pandemic together with analysis of 241 
bilateral samples provide important controls for this study, and the similarities between results 242 
from the spot card and the liquid colostrum demonstrate the value of the spot card collection 243 
method.  244 
Spot card colostrum from all but one of the 15 participants exposed to SARS-CoV-2 245 
exhibited IgA, IgG and IgM reactivities to RBD. The similarity in reactivity levels between the 246 
two breasts provides confidence in the assay; comparable levels of immunoglobulins across 247 
breasts are expected20 except when there are local infections. The range of IgA, IgG and IgM 248 
reactivities to RBD is not easily explained by the time since onset of symptoms. The single 249 
COVID-19pos participant whose colostrum had no antibody reactivity to RBD (P15) had onset of 250 
symptoms 98 days before delivery, while one of the participants with high levels of IgA and IgG 251 
reactivities to RBD (P16) had onset of symptoms 144 days before delivery (Figure S2). 252 
 253 
Results in the context of what is known 254 
 The presence of SARS-CoV-2-specific IgA and IgG in bilateral liquid colostrum of two 255 
pre-COVID-19 controls, and the left breast of a third control (P20), could indicate a prior 256 
infection that elicited a humoral response that cross-reacted with SARS-CoV-2-RBD. This 257 
would be consistent with findings from Pace et al, who demonstrated that levels of SARS-CoV-258 
2-specific milk IgA and IgG correlated with IgA and IgG concentrations specific to the S-protein 259 
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of 229E coronavirus4. Alternatively, Isho et al also observed elevated saliva IgA and IgG 260 
reactivities to SARS-CoV-2-RBD among their pre-COVID-19 controls, but did not attribute the 261 
response to a prior coronavirus infection21. We were concerned that the reactivity in the left 262 
breast of P20 could have been due to experimental error, however, a repeat analysis confirmed 263 
the IgA and IgG reactivities. 264 
Interestingly, IFNg is the only cytokine that was not elevated in the colostrum of COVID-265 
19pos participants. Many viruses, including SARS-CoV-2, have developed mechanisms to evade 266 
the antiviral type-1 interferon pathway, leading to its reduced expression and moderate to low 267 
expression of various interferon stimulated genes, including IFNg6,22–25. While there are some 268 
conflicting reports, the lack of increased IFNg expression associated with COVID-19 is 269 
consistent with our findings in colostrum and needs further investigation.  270 
An inverse relationship between IL-10 and proinflammatory cytokines is normal and 271 
expected, as IL-10 is upregulated in T-cells in response to inflammation and acts to reduce 272 
inflammatory cytokines. However, in SARS-CoV-2 infections, there is evidence that cytokines 273 
are not secreted by T-cells, but by recruited monocytes and macrophages, causing IL-10 to 274 
remain elevated26–28. We show that both IL-10 and inflammatory cytokines are increased in 275 
colostrum. A time-course study with serial milk collections and analysis of both cytokines and 276 
immune cells would contribute greatly to our understanding of the inflammatory response to 277 
SARS-CoV-2 infections. 278 
Spot cards provide an efficient means of collecting colostrum. All 16 participants 279 
consented to provide spot card followed by liquid colostrum. That the liquid sample was 280 
collected from only 6 participants is likely due to the smaller volume requested for the spot card, 281 
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and greater ease for the staff, as the spot card can be left to dry at RT for several hours, while the 282 
liquid colostrum needs to be quickly frozen. 283 
 284 
Clinical Implications 285 
The possible protection from SARS-CoV-2-specific antibodies detected in colostrum has 286 
clinical implications regarding the discussion about breast-feeding after exposure to the virus. 287 
SARS-CoV-2-specific immune response was detected in the colostrum of women who had their 288 
first positive test and symptoms more than four months before delivery, women who were 289 
symptomatic at delivery, as well as asymptomatic women who had a first positive test at 290 
delivery. The detection of SARS-CoV-2-specific antibodies in these women with diverse 291 
COVID-19 disease experiences provides objective data for the value of initiating breast-feeding 292 
despite SARS-CoV-2 infection. 293 
 294 
Research Implications 295 
 Given that the differences between the spot card and liquid samples for IgA, IgG and IgM 296 
reactivities to RBD are not all unidirectional, we can assume that differences do not simply 297 
reflect collection method. Indeed, the differences between spot card and liquid reactivities for 298 
P04 could demonstrate antibody evolution in colostrum: i.e., a switch from high IgA to high IgM 299 
(Figure 2A).  300 
Cytokine concentrations are significantly higher in the liquid colostrum from COVID-301 
19pos as compared to pre-COVID-19 participants (Figure 3) suggesting a SARS-CoV-2-specific 302 
response. However, there is concern that cytokines could be degraded in archived samples. An 303 
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argument against sample degradation is the high levels of IFNg for two of the pre-COVID-19 304 
controls.  305 
Calculated concentrations of cytokines differed between the spot card-eluates and liquid 306 
colostrum among the five COVID-19pos participants who provided both sample types, with the 307 
levels being generally higher in the liquid samples (Figure S4). Four participants show an 308 
increase in the liquid samples, and one participant shows a decrease. Differences could reflect 309 
rapid changes in levels over days. Use of the spot card with serial collections and direct 310 
comparisons between liquid and spot card samples are needed in future work.  311 
 312 
Conclusion 313 
Our study is among the first to demonstrate the presence of SARS-CoV-2-specific antibodies in 314 
colostrum and describes for the first time elevated cytokines in colostrum from women exposed 315 
to SARS-CoV-2. The evolution and duration of the antibody response as well as dynamics of the 316 
cytokine response remain to be determined. Given the feasibility of the collection method, and 317 
the ability to detect antibodies and cytokines, our results indicate that future large-scale studies 318 
can be conducted with milk easily collected on paper spot cards. 319 
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 426 
Table 1. Demographics of participants who donated colostrum  
 2020 (n = 16*) 2011-2013 (n = 8) p-value 
Mean Range Mean Range 
Age (year) 32 21-39 34 29-40 0.64 
BMI (kg/m2) 34 24-43 27 22-33 0.08 
 
 n Percent n Percent  
Parity 
  1 
  2 
  3 
  4 



























  Asian American 
  Hispanic 
  White Hispanic 
  White 


























*Includes one participant who provided bilateral colostrum during the COVID-19 pandemic but who tested 
negative for SARS-CoV-2 by diagnostic RT-PCR and had no symptoms.  
 427 
  428 
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 429 
Table 2. Concentrations of cytokines in human colostrum  
 COVID-19 Participants: March & September, 20201 Pre-COVID Controls: 2011-2013 
 Spot Card Colostrum n = 302 Liquid Colostrum n = 103 Liquid Colostrum n = 164 
Analytes Mean IQR % Det5 Mean IQR % Det Mean IQR % Det 
IFNg 2.78 0.78-3.34 84.4 20.55 2.22-26.61 91.7 13.38 0.14-11.17 69 
TNFa 2.11 0.67-2.98 100 9.32 2.56-11.66 100 0.53 0.06-0.54 75 
IL-1b 2.20 0.25-1.67 84.4 6.16 2.47-6.61 100 0.18 0.05-0.20 81 
IL-2 1.49 0.48-1.91 100 3.38 0.44-5.67 91.7 0.19 0.05-0.21 69 
IL-4 0.24 0.07-0.32 93.8 0.76 0.04-1.19 75 0.02 0.01-0.02 50 
IL-6 0.72 0.13-0.83 84.4 53.44 4.96-88.75 100 1.66 0.11-1.08 81 
IL-8 498 92-758 100 1045 511-1512 100 96.93 20 - 57 100 
IL-10 0.49 0.16-0.68 96.7 2.67 0.28-3.71 100 0.11 0.02-0.09 69 
IL-12 0.86 0.36-0.96 96.7 2.69 0.21-4.09 75 0.16 0.04-0.08 50 
IL-13 5.81 2.79-7.87 100 16.47 5.38-22.44 100 2.17 0.89-2.22 81 
Concentration is pg/mL for all analytes. If both technical replicates were above the lower limit of detection (LLOD), 
the final concentration was the mean of the two levels. If both technical replicates were below the LLOD, the final 
concentration was computed as LLOD divided by the square root of 2 29   
1 = Bilateral colostrum provided by 15 COVID-19-positive participants. 
2 = Spot card samples from the left and right breasts of 15 women diagnosed with COVID-19 collected within 48 
hours of delivery 
3 = Liquid samples from the left and right breasts of 5 women diagnosed with COVID-19 collected 1-2 days after 
collection of the spot card samples 
4 = Liquid samples from the left and right breasts of 8 women who donated colostrum during 2011-2013 collected 1-
3 days after delivery 
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Table 3. Correlation of IgA, IgG and IgM concentrations with cytokine concentration in bilateral colostrum eluted from spot cards obtained 
from 15 participants diagnosed with COVID-19  
  IgA IgG IgM 
Predictors Estimates CI p Estimates CI p Estimates CI p 
(Intercept) 370.13 29.75 – 710.51 0.034 68.39 36.49 – 100.30 <0.001 181.58 55.48 – 307.67 0.007 
IFNg -47.97 -146.16 – 50.21 0.321 -11.54 -20.75 – -2.34 0.016 -12.02 -48.39 – 24.35 0.499 
TNFa 94.12 -280.66 – 468.91 0.607 32.93 -2.19 – 68.06 0.065 110.55 -28.29 – 249.39 0.113 
IL-1b 20.11 -69.13 – 109.34 0.644 7.10 -1.27 – 15.46 0.092 50.34 17.28 – 83.39 0.005 
IL-2 -6.33 -438.19 – 425.53 0.976 4.76 -35.72 – 45.24 0.809 37.28 -122.71 – 197.27 0.633 
IL-4 -686.62 -4479.87 – 3106.63 0.710 5.13 -350.42 – 360.68 0.976 -236.93 -1642.17 – 1168.30 0.729 
IL-6 -186.35 -1051.47 – 678.77 0.659 -1.13 -82.22 – 79.96 0.977 -62.81 -383.30 – 257.68 0.688 
IL-8 0.24 -0.58 – 1.06 0.554 0.01 -0.06 – 0.09 0.744 0.10 -0.21 – 0.40 0.519 
IL-10 1170.03 -680.23 – 3020.30 0.203 158.59 -14.84 – 332.02 0.071 330.69 -354.75 – 1016.14 0.327 
IL-12 550.36 -289.71 – 1390.44 0.187 26.66 -52.08 – 105.40 0.489 -42.13 -353.34 – 269.09 0.781 
IL-13 -161.36 -300.18 – -22.54 0.025 -30.10 -43.11 – -17.09 <0.001 -81.82 -133.25 – -30.40 0.003 
Observations 30 30 30 
R2 / R2adjusted 0.626 / 0.448 0.778 / 0.672 0.649 / 0.482 
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FIGURE LEGENDS 433 
Figure 1. Overview of participants’ COVID-19 symptoms relative to their time of delivery. 434 
Participant P01 tested negative for SARS-CoV-2 (indicated as not applicable: N/A). Participants 435 
P02, P04, P05, P08, P10, and P11 reported no COVID-19-related symptoms (indicated as no 436 
symptoms: NS) despite positive PCR tests.  437 
 438 
Figure 2. Distinct reactivities for IgA, IgG and IgM in colostrum from COVID-19-infected 439 
and pre-COVID-19 control participants. (A) Mean OD values for IgA, IgG and IgM in 440 
colostrum from six participants who provided both bilateral colostrum on spot cards (filled bars, 441 
donation 1) and bilateral liquid colostrum (open bars, donation 2). (B) Mean OD values for IgA, 442 
IgG and IgM in colostrum obtained from the remaining 10 participants who provided bilateral 443 
colostrum on spot cards only. (C) Mean OD values for IgA, IgG and IgM in bilateral liquid 444 
colostrum obtained from 8 pre-COVID-19 control participants. For A and B, all spot card 445 
samples were collected within 48 hours postpartum and all liquid colostrum was collected 1-2 446 
days after the spot card collection. For C, all liquid samples were collected 1-3 days postpartum. 447 
Dotted lines indicate cut-off value set at twice the mean OD of secondary-only antibody 448 
reactivity across all plates. OD values for all samples are the means of technical duplicates.    449 
 450 
Figure 3. Elevated inflammatory markers in colostrum obtained from COVID-19 451 
participants. Concentrations of cytokines in liquid colostrum from the five COVID-19 452 
participants, the 2020 COVID-19-negative participant (x), and the pre-COVID-19 pandemic 453 
controls (  ) were measured with MSD technology. The plots show the median concentration of 454 
each cytokine (middle line). Red circles (   ) indicate bilateral colostrum provided by participants 455 
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who exhibited COVID-19-related symptoms. Open circles (   ) below median values for all 456 
analytes indicate bilateral colostrum provided by participants P02 and P04 who did not exhibit 457 
COVID-19-related symptoms despite having positive PCR tests. Open circles above median 458 
values for all analytes indicate bilateral colostrum provided by participant P05 who did not 459 
exhibit COVID-19-related symptoms but reported having influenza 3 months before delivery.   460 
 . CC-BY-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted January 4, 2021. ; https://doi.org/10.1101/2021.01.03.20248715doi: medRxiv preprint 
 . CC-BY-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)















IgM spotcard colostrum 






d L R L R L R L R L R L R












































 . CC-BY-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)




























































































































 . CC-BY-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted January 4, 2021. ; https://doi.org/10.1101/2021.01.03.20248715doi: medRxiv preprint 
